respiratory management of the patient with duchenne ...transition of respiratory care from pediatric...
TRANSCRIPT
PEDIATRICS Volume 142, number s2, October 2018:e20180333HSUPPLEMENT ARTICLE
Respiratory Management of the Patient With Duchenne Muscular DystrophyDaniel W. Sheehan, PhD, MD, a David J. Birnkrant, MD, b Joshua O. Benditt, MD, c Michelle Eagle, PhD, d Jonathan D. Finder, MD, e John Kissel, MD, f Richard M. Kravitz, MD, g Hemant Sawnani, MD, h Richard Shell, MD, i Michael D. Sussman, MD, j Lisa F. Wolfe, MDk
aDepartment of Pediatrics, Oishei Children’s Hospital and The University at Buffalo, Buffalo, New York; bDepartment of Pediatrics, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio; cDepartment of Medicine, University of Washington, Seattle, Washington; dUniversity of Newcastle, Newcastle upon Tyne, United Kingdom; eDepartment of Pediatrics, University of Pittsburgh Medical Center Children’s Hospital of Pittsburgh and University of Pittsburgh, Pittsburgh, Pennsylvania; fDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio; gDepartment of Pediatrics, Duke University, Durham, North Carolina; hDepartment of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; iDepartment of Pediatrics, Nationwide Children’s Hospital and The Ohio State University, Columbus, Ohio; jShriners Hospital for Children, Portland, Oregon; and kDepartment of Medicine, Northwestern University, Evanston, Illinois
Drs Sheehan and Birnkrant served as chairpersons for the Duchenne Muscular Dystrophy Care Considerations Respiratory Management Working Group, as convened by the Centers for Disease Control and Prevention, and drafted the initial manuscript; Drs Benditt, Eagle, Finder, Kissel, Kravitz, Sawnani, Shell, Sussman, and Wolfe all served on the Duchenne Muscular Dystrophy Care Considerations Respiratory Management Working Group, as convened by the Centers for Disease Control and Prevention, and contributed to the development of corresponding recommendations; and all authors reviewed and revised the manuscript, approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.
DOI: https:// doi. org/ 10. 1542/ peds. 2018- 0333H
Accepted for publication Jul 26, 2018
Address correspondence to Daniel W. Sheehan, PhD, MD, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, 955 Main St, Room 7179, Buffalo, NY 14203. E-mail: [email protected]
With progressive loss of muscle strength, individuals with Duchenne muscular dystrophy (DMD) are at risk for respiratory complications, including ineffective cough, lower respiratory tract infections, nocturnal hypoventilation and/or obstructive sleep apnea (OSA), and ultimately, daytime respiratory failure.1 – 7 Immobility, scoliosis, heart failure, malnutrition, and dysphagia with aspiration also may contribute to progressive respiratory dysfunction.8
The guidelines or recommendations in this article are not American Academy of Pediatrics policy and publication herein does not imply endorsement.
In 2010, Care Considerations for Duchenne Muscular Dystrophy, sponsored by the Centers for Disease Control and Prevention, was published in Lancet Neurology, and in 2018, these guidelines were updated. Since the publication of the first set of guidelines, survival of individuals with Duchenne muscular dystrophy has increased. With contemporary medical management, survival often extends into the fourth decade of life and beyond. Effective transition of respiratory care from pediatric to adult medicine is vital to optimize patient safety, prognosis, and quality of life. With genetic and other emerging drug therapies in development, standardization of care is necessary to accurately assess treatment effects in clinical trials. This revision of respiratory recommendations preserves a fundamental strength of the original guidelines: namely, reliance on a limited number of respiratory tests to guide patient assessment and management. A progressive therapeutic strategy is presented that includes lung volume recruitment, assisted coughing, and assisted ventilation (initially nocturnally, with the subsequent addition of daytime ventilation for progressive respiratory failure). This revision also stresses the need for serial monitoring of respiratory muscle strength to characterize an individual’s respiratory phenotype of severity as well as provide baseline assessments for clinical trials. Clinical controversies and emerging areas are included.
abstract
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
PEDIATRICS Volume 142, number s2, October 2018 S63
When untreated, patients experience dyspnea and are at risk for prolonged hospitalizations and death from mucus plugging, severe pneumonia, or respiratory-induced cardiac arrhythmias.1 – 7, 9
The aim of respiratory care is to prevent these potential complications and manage them in a timely way. A structured, anticipatory approach to respiratory management requires monitoring respiratory muscle strength as well as initiating lung volume recruitment, assisted coughing, nocturnally assisted ventilation, and eventually daytime ventilatory support. These therapies have been shown to improve quality of life and prolong patient survival.9 – 17
Respiratory management is a multidisciplinary endeavor. In addition to home caregivers, the care team should include a physician and respiratory therapist (or physical therapist, in some health care systems) who can perform pulmonary function testing and sleep studies and are skilled in managing lung volume recruitment, manual and mechanically assisted coughing, noninvasive ventilation with associated interfaces, tracheostomies, and mechanical ventilators.
OBJECTIVES
The 2018 DMD Care Considerations, sponsored by the Centers for Disease Control and Prevention, seeks to preserve a fundamental strength of the 2010 version of the guidelines, that is, reliance on a limited number of respiratory tests to guide patient assessment and management.7, 18, 19 These tests are, within the limitations of the existing scientific literature, well studied, clinically relevant and reproducible, and can be measured by using only a few pieces of widely available and relatively inexpensive equipment, namely, a spirometer, a peak flowmeter, a manometer, and a pulse oximeter. By optimizing the
practicality and applicability of our core recommendations, we seek to minimize the barriers to achieving the highest level of DMD respiratory care for clinicians in all practice venues, including those with limited access to professional and physical resources.
This revision also contains new recommendations not found in the 2010 Care Considerations document. In the current version, we simplify the criteria for initiating assisted coughing and assisted ventilation and emphasize noninvasive modalities of ventilation. We recommend respiratory interventions at a somewhat higher level of pulmonary function compared with the 2010 criteria and endorse using similar criteria for initiating both assisted coughing and assisted ventilation, thereby advocating for simultaneous, rather than sequential, initiation of these key therapies. With this strategy, we seek to emphasize the need for anticipatory respiratory management before patients develop complications.
SPECIFIC CORE RECOMMENDATIONS
Ambulatory Stage
While ambulatory, individuals with DMD should learn pulmonary function testing and, with their caregivers, be educated about assessing and managing respiratory complications. Starting at 5 to 6 years of age, annual measurements of seated forced vital capacity (FVC) should be made, to train patients in spirometry and to start assessing each patient’s course of pulmonary function over time (Fig 1). Serial monitoring of pulmonary function is critical because FVC will eventually decline silently (in the absence of dyspnea) in nonambulatory patients. In general, FVC increases with growth until the loss of ambulation, at which point FVC will sequentially peak, plateau, and then deteriorate over time.20 – 22 Although this general
description is accurate, the age at peak FVC, the level of the maximal FVC value, and the subsequent rate of deterioration in FVC can all vary greatly among individual patients, even among patients who share the same dystrophin mutation (Fig 2).7, 23, 24 Thus, serial measurement of FVC is essential because it allows clinicians to assess the respiratory course of individual patients over time, characterizing their personal respiratory trajectory and phenotypic severity.
It is important to also consider the respiratory implications of glucocorticoid therapy. Use of glucocorticoids can prolong the period of ambulation and preserve pulmonary function in individuals with DMD.25 However, weight gain is a common side effect. As a result, OSA is the most common form of sleep-disordered breathing among steroid-treated patients in the ambulatory and early nonambulatory stages of DMD, affecting patients as young as age 12 years. OSA is positively correlated with BMI.26 Sleep evaluations with capnography are indicated for individuals with sleep-disordered breathing symptoms and are discussed in more detail in the sections that follow.
To prevent or minimize respiratory illnesses, individuals should receive immunization with the inactivated influenza vaccine yearly and pneumococcal vaccines (including pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine) according to the recommended schedule. Guidelines for the timing and frequency of these vaccines are available from the Centers for Disease Control and Prevention27 and from the Parent Project Muscular Dystrophy.28
Early Nonambulatory Stage
Respiratory complications and the need for respiratory interventions primarily occur after the loss of independent ambulation. Respiratory
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
SHEEHAN et alS64
assessments and interventions indicated during this stage are shown in Fig 1.
When FVC is ≤60% predicted, lung volume recruitment is indicated to preserve respiratory system compliance. Lung volume recruitment is achieved with the use of a self-inflating manual ventilation bag or mechanical insufflation–exsufflation device applied once or twice daily29 – 32 (see protocols for this procedure on the CANVent Web site: http:// canventottawa. ca/ EducationModules/ Phase/ 2). Some individuals with DMD require surgery for progressive scoliosis. Specific guidelines have been published addressing the pre- and postoperative respiratory care of
these patients.33, 34 Preoperative polysomnography should be considered for individuals who are cognitively impaired and unable to reliably perform pulmonary function testing.
Late Nonambulatory Stage
Individuals with DMD eventually develop a weak, ineffective cough associated with chest congestion from retained respiratory secretions, putting them at risk for atelectasis, pneumonia, ventilation-perfusion mismatch, and progression to respiratory failure when they acquire what would otherwise be a mild respiratory tract infection. Therefore, before the onset of these complications, the next respiratory
intervention is to initiate manual and/or mechanical cough assistance, the criteria for which are shown in Fig 1.35 – 52 For videos and practical guidance, see the CANVent Web site: http:// canventottawa. ca/ EducationModules/ Phase/ 2.
When assisted coughing is begun, a pulse oximeter should be available in the home to aid clinical assessment because mild hypoxemia (pulse oxygen saturation [SpO2]: <95% in room air) is an indication to increase the frequency of assisted coughing. Such a strategy can be used to prevent mucus plugging, atelectasis, and pneumonia as well as hospitalization8 (see Supplemental Fig 3, Duke Airway Clearance protocol). During acute respiratory
FIGURE 1Care considerations for respiratory management of DMD patients by stage of disease. The components of pulmonary management for patients during each of the 3 major stages of DMD are described in this figure: ambulatory, early nonambulatory, and late nonambulatory. (Reproduced with permission from Birnkrant DJ, Bushby K, Bann CM, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopedic management. Lancet Neurol. 2018;17[4]:348. See that text for additional details.)
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
PEDIATRICS Volume 142, number s2, October 2018 S65
illnesses, antibiotic therapy should be added for patients who have 3 of the following 5 clinical signs of pneumonia: fever, elevated white blood cell count or C-reactive protein level, sputum production, a pulmonary infiltrate on the chest radiograph, or hypoxemia or respiratory distress.53
Later in this stage of the disease, individuals require assisted ventilation during sleep to prolong their survival. When vital capacity falls below 1 L, mean survival is just 3.1 years without the use of assisted ventilation.54
Indications for nocturnal assisted ventilation are listed in Fig 1.7, 26, 33, 55 – 58 Nocturnal assisted ventilation is indicated when individuals with DMD have abnormal sleep studies. These studies include overnight oximetry, combination oximetry–capnography, and polysomnography with capnography. The benefit of capnography is that it can be used to detect changes in alveolar ventilation that remain undetected with oximetry alone (eg, when the
patient’s SpO2 is on the flat portion of the oxyhemoglobin dissociation curve). For symptoms of sleep-disordered breathing, patients should have sleep studies as often as annually, when such studies are available. In addition to the criteria in Fig 1, nocturnally assisted ventilation is indicated if sleep study results show any of the following: end-tidal or transcutaneous carbon dioxide (CO2) >50 mm Hg for ≥2% of sleep time, a sleep-related increase in end-tidal or transcutaneous CO2 of 10 mm Hg above the awake baseline for ≥2% of sleep time, SpO2 ≤88% for ≥2% of sleep time or for at least 5 minutes continuously, or an Apnea–Hypopnea Index ≥5 events per hour.59, 60 For case examples and guidance on monitoring for signs and symptoms of respiratory failure, see the CANVent Web site at http:// www. ohri. ca/ NIVAM/ Default. aspx? SlideID= 457.
Even in DMD patients with OSA, continuous positive airway pressure therapy should be avoided because individuals with DMD will eventually
require assisted ventilation to manage hypoventilation. Noninvasive ventilation also can be used during and after procedures involving sedation or anesthesia and, in conjunction with assisted coughing, to successfully extubate individuals who are mechanically ventilated for acute respiratory failure (see Supplemental Fig 4, Duke Neuromuscular Patient Extubation Protocol).61
The process of extending nocturnally assisted ventilation into daytime and, ultimately, 24-hour-per-day ventilation will often be guided by the patient himself. With progressive respiratory muscle weakness, individuals become increasingly dyspneic and tachypneic while awake, despite nocturnally assisted ventilation. Indications for daytime assisted ventilation all reflect symptomatic hypoventilation (Fig 1). Individuals with DMD who have very low FVCs (eg, <680 mL6) are at particular risk of awake hypoventilation.6
Progression toward continuous use of a noninvasive or invasive ventilator means that the individual with DMD is essentially using the device for life support and should be provided with a back-up ventilator and a manual resuscitation bag in case the primary ventilator malfunctions. In addition, several batteries and/or a generator are needed to run the ventilation device during a power outage, and batteries are needed for mobility and travel. Arrangements should be made for attaching the ventilation device to the patient’s wheelchair, so that the patient can achieve mobility, optimizing his quality of life.
In persons with DMD, hypoxemia is usually caused by hypoventilation and/or ventilation–perfusion mismatch related to mucus plugging. We therefore strongly caution against the use of supplemental oxygen therapy without simultaneous use of assisted ventilation and assisted
FIGURE 2FVC versus age for 2 brothers with the same genotype. How pulmonary function can vary even among individual patients with the same genotype is shown in this figure. One brother has a favorable respiratory phenotype, with FVC preserved over time, whereas the other brother has a more severe phenotype, with a lower value for peak FVC, followed by more rapid decline. (Reprinted with permission from Birnkrant DJ, Ashwath ML, Noritz GH, et al. Cardiac and pulmonary function variability in Duchenne/Becker muscular dystrophy: an initial report. J Child Neurol. 2010;25[9]:1111.)
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
SHEEHAN et alS66
coughing. With oxygen therapy alone, the underlying causes of hypoxemia remain untreated; hypoventilation and respiratory acidosis can occur and respiratory drive may be impaired.62 In contrast, when accompanied by assisted ventilation and assisted coughing, oxygen therapy can be used safely to maintain adequate oxygenation during acute respiratory illnesses, especially when blood CO2 levels are monitored.
CLINICAL CONTROVERSIES
The issue of whether patients with DMD should be ventilated by tracheostomy or noninvasively, such as with a nasal mask or pillows, is a clinical controversy that evokes strong opinions among experts in the field. Some centers initiate assisted ventilation noninvasively and then transition patients to tracheostomy as their pulmonary function declines (eg, when the patient needs 16 hours per day or more of assisted ventilation). At other centers, patients receive a tracheostomy as soon as they start assisted ventilation.63, 64 However, the use of noninvasive assisted ventilation for up to 24 hours per day is supported in a growing body of literature, as well as in clinical experience.11, 16, 65, 66 When it is well tolerated, our panel strongly recommends noninvasive assisted ventilation instead of tracheostomy.67
During sleep, many individuals with DMD default to their noninvasive ventilator’s back-up rate of breathing. It is, therefore, essential for DMD patients to use noninvasive ventilators that can function in both spontaneous and timed modes, that is, devices that ensure a minimum breathing rate, triggered by a timer, to prevent apnea. Options for 24-hour-per-day noninvasive ventilation include daytime mouthpiece or “sip” ventilation using a portable volume ventilator during
wakefulness and switching to a bilevel device during sleep68 (see the sip protocol at http:// canventottawa. ca/ Nivam/ Phases/ 4. aspx). Twenty-four–hour-per-day nasal ventilation with a bilevel device alone can also be well tolerated. Nevertheless, the initiation of assisted ventilation via tracheostomy may be preferable for some patients with DMD, and indications for tracheostomy are listed in Fig 1.69 It is important to recognize that some patients who begin assisted ventilation noninvasively may eventually require “rescue tracheostomy” in the setting of critical illness (eg, during a hospitalization) when they require intubation and subsequently fail several attempts to be extubated to noninvasive ventilation.59, 61, 70 This clinical scenario may become more common as individuals who have used noninvasive ventilation for a decade or more live into their 30s and beyond.9 Choosing the best mode of assisted ventilation for individuals with DMD is a complex issue. Issues to consider include the following: the clinical course of the patient, individual patient preference, the usual practices and skills of the patient’s clinicians, local care standards, and the availability of needed resources, including skilled home caregivers. Currently, no known predictors exist to identify individuals with DMD who will eventually fail noninvasively assisted ventilation. Such predictors would be useful if they allowed patients who are ventilated noninvasively to undergo elective tracheostomy while they are healthy, avoiding the risks and morbidity of rescue tracheostomy in the setting of critical illness. Regarding risk factors, noninvasive respiratory aids are especially challenging to use when individuals with advanced DMD develop acute respiratory illnesses and when they have chronic difficulty handling their oropharyngeal secretions due to swallowing dysfunction.
EMERGING AREAS THAT REQUIRE ADDITIONAL RESEARCH AND VALIDATION
In the recommendations above, we describe a set of core diagnostic tests and therapeutic interventions that are necessary for optimal respiratory evaluation and treatment of patients with DMD. Various other diagnostic tests and therapeutic techniques also may be appropriate for use in selected patients; they have potential clinical use and may be appropriate for specialty clinics, but they require further study and validation. These tests include the following: forced expiratory volume in 1 second, peak expiratory flow rate, sniff nasal inspiratory pressure, inspiratory flow reserve, and rapid shallow breathing index. Both the potential use and limitations of these tests were discussed in a recent workshop and related publication.71 Additional emerging diagnostics that warrant further research include serial measurement of the following: slow vital capacity, maximum insufflation capacity, the maximum insufflation capacity–FVC difference, supine FVC, assisted cough peak flow and highest flow generated during an inspiratory FVC maneuver (maximum inspiratory flow and V'I, max [FVC]), optoelectronic plethysmography, measurements of diaphragmatic compound muscle potential, and respiratory impedance.72 – 78 When available, supine FVC monitoring can add important information because, with progressive diaphragmatic weakness, the difference between seated and supine FVC increases, and patients experience nocturnal symptoms and declining pulmonary reserve.72, 73 Additionally, once they are validated for the DMD population and have been shown to have predictive value for initiating respiratory therapies, the results of questionnaire tools, such as the modified Borg score, have the potential to be used to supplement pulmonary function testing.74, 75
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
PEDIATRICS Volume 142, number s2, October 2018 S67
Areas with significant therapeutic implications for respiratory health that require additional research include the following: the potential benefits of respiratory muscle training, the relationship between nutrition and respiratory muscle strength, the optimal timing for gastrostomy placement, and the contribution of chronic aspiration to the respiratory complications of DMD.76 – 81 Other potentially beneficial therapies include high-frequency chest oscillation, intrapulmonary percussive ventilation, and biphasic cuirass ventilation or airway clearance.82, 83 Another area that merits further research is the potential for improved mucus clearance and assisted ventilation devices to prevent cardiac death by eliminating fatal arrhythmias induced by transient hypoxemia and/or acidosis caused by mucus plugging or hypoventilation.10
FUTURE DIRECTIONS
Genetic and molecular therapies are being developed for DMD at an unprecedented rate.84 Because respiratory complications are major determinants of survival and quality of life, it is critically important to consider the best methodology for evaluating the respiratory effects of these new therapies.
Use of Respiratory Devices During Clinical Trials of Emerging Therapies
Contemporary methods of respiratory management, such as those endorsed in the Specific Core Recommendations section of this article, have been used to prolong patient survival. Respiratory care in which these methods are employed should, therefore, be specified in the methodology of clinical trials of emerging DMD therapies. This includes initiation of lung volume recruitment, assisted coughing, and assisted nocturnal and daytime ventilation. At present, adherence with best practice guidelines appears
to be lacking.63, 84 – 86 Adherence to respiratory guidelines like those in this statement, as well as standardized approaches to cardiac management and treatment with glucocorticoids, is needed to minimize variability of care, improve patient outcomes, and assess the effects of new treatments.
Development of Clinically Meaningful Pulmonary Outcome Measures
FVC as a Primary Outcome Measure
The development of reproducible and clinically meaningful pulmonary outcome measures will be essential to assess the efficacy of new therapies. For a detailed discussion, the reader is referred to the “Pulmonary Endpoints in Duchenne Muscular Dystrophy” workshop publication.71 Key recommendations include the use of seated FVC as the primary pulmonary outcome measure. Forced expiratory volume in 1 second, maximum inspiratory pressure, maximum expiratory pressure, peak cough flow, peak expiratory flow rate, and sniff nasal inspiratory pressure are considered to be secondary end points, pending further validation. Tests of seated FVC should be performed by a technician with suitable training and validated by using American Thoracic Society criteria that have been modified for patients with DMD.21
The Natural History of FVC in Patients With DMD: Pulmonary Phenotypic Variability
In DMD patients, the pattern of FVC over time is typically composed of 3 stages: while the patient is ambulatory, FVC rises annually; during the early nonambulatory stage, FVC plateaus and remains constant for several years; and during the late nonambulatory stage, FVC progressively declines each year until death. In theory, this pattern should allow for prediction of an individual patient’s respiratory course over time. However, pulmonary function can vary significantly among
individual patients, even when the patients have identical dystrophin mutations, such as brothers with DMD.7, 23, 24 For example, in Fig 2, data are shown from 2 brothers with the same mutation who have highly discordant pulmonary function.87 The poor correlation between dystrophin genotype and pulmonary phenotype makes it difficult to predict the pulmonary course of an individual patient on the basis of genotype alone. Pulmonary outcome measures must be viewed in the context of each individual’s expected course of pulmonary function over time. For example, when evaluating the effect of a therapy on a particular patient, it is necessary to know if the patient is in the rising, plateauing, or declining stage of FVC. In addition, it is necessary to know the patient’s respiratory phenotype (FVC trajectory over time), including the expected level of the patient’s peak FVC, the age at which he will attain peak FVC, and the expected rate of subsequent FVC decline. Without this information, preservation of pulmonary function over time, for example, could be falsely attributed to the effect of a new therapy, rather than the patient’s favorable respiratory phenotype. Because respiratory phenotypic variability is common, results from studies in which researchers examined the effect of new therapies on pulmonary function in aggregate (ie, using pooled FVC data, without regard for each patient’s respiratory stage and respiratory phenotype) will be confounded by the subjects’ variable respiratory stages and phenotypes.
Identification of a patient’s respiratory stage and phenotype involves major challenges, including the need for serial measurement of pulmonary function over time and categorization of the severity of a patient’s respiratory phenotype early in the course of his disease, when new therapies are likely to be initiated. Humbertclaude et al20
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
SHEEHAN et alS68
found that corticosteroid-naïve boys who lost ambulation before age 8 years had a more severe respiratory phenotype, characterized by a lower peak FVC, which occurred at a younger age and was followed by a more rapid decline compared with patients who remained ambulatory longer. Early predictors of a patient’s long-term respiratory course and phenotype, like age at loss of ambulation, may turn out to be critically important for the evaluation of new DMD therapies.
Proposed Criteria for Assessing the Effect of New Therapies on FVC
The committee endorses that a therapy for DMD is beneficial to the respiratory system if use of that therapy results in a rise in the patient’s FVC that is larger than predicted (when the patient is in the rising stage of pulmonary function), in an unexpectedly prolonged stabilization of the patient’s FVC (when the patient is in the plateau stage of pulmonary function), or in a fall in the patient’s FVC that is smaller than predicted (when the patient is in the declining stage of pulmonary function). In addition, the committee recommends that the absolute value of a patient’s FVC measurements be interpreted in the context of his pulmonary
phenotypic severity, including the expected level of his peak FVC, the age at which his peak FVC should occur, and the subsequent course that the patient’s FVC is expected to follow.
Cardiopulmonary Interactions and Phenotypic “Disconnects”Finally, it is important to understand how pulmonary outcome measures relate to patient survival. Causes of death in contemporary DMD populations have shifted from pulmonary to cardiac complications. This observation was confirmed in a recent study in which authors suggested that when DMD patients are treated with assisted ventilation according to current guidelines, then cardiac function is the main determinant of their survival.9 Additional evidence suggests that individual patients may have a phenotypic disconnect between their respiratory and cardiac function. For example, in the study cited above, prolonged survivors of DMD had good heart function but poor pulmonary function. Patients who experienced early death had the opposite: poor heart function and good lung function. This variable phenotypic expression by different body systems may be caused by genetic modifiers that preferentially
affect cardiac or respiratory (ie, skeletal) muscle.88, 89 With these observations, it is suggested that pulmonary outcome measures may not be directly related to patient survival. For example, if an individual patient has a detrimental genetic modifier that preferentially affects cardiac muscle, then a therapy that improves skeletal muscle strength, and thus pulmonary function, may not prolong that patient’s survival because that patient is likely to die of progressive cardiomyopathy. Authors of studies of emerging therapies should not equate improved pulmonary function with improved patient survival because in a subset of patients, cardiac function will be the main determinant of their survival. Instead, it is necessary to examine both the pulmonary and cardiac function of each individual patient over time to assess the effect of new therapies on his survival.
ABBREVIATIONS
CO2: carbon dioxideDMD: Duchenne muscular
dystrophyFVC: forced vital capacityOSA: obstructive sleep apneaSpO2: pulse oxygen saturation
REFERENCES
1. Barbé F, Quera-Salva MA, McCann C, et al. Sleep-related respiratory disturbances in patients with Duchenne muscular dystrophy. Eur Respir J. 1994;7(8): 1403–1408
2. Culebras A. Sleep-disordered breathing in neuromuscular
disease. Sleep Med Clin. 2008;3(3): 377–386
3. Dohna-Schwake C, Ragette R, Teschler H, Voit T, Mellies U. Predictors of severe chest infections in pediatric neuromuscular disorders. Neuromuscul Disord. 2006;16(5):325–328
4. Hukins CA, Hillman DR. Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2000;161(1):166–170
5. Phillips MF, Smith PE, Carroll N, Edwards RH, Calverley PM. Nocturnal oxygenation and prognosis
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2018 by the American Academy of Pediatrics
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
FUNDING: Supported in part by Cooperative Agreement NU38OT000167, funded by the Centers for Disease Control and Prevention.
POTENTIAL CONFLICT OF INTEREST: Dr Birnkrant has United States and international patents and patent applications for respiratory devices; he is also a former consultant to the Hill-Rom corporation. Dr Benditt is a consultant for (and has stock options in) Ventec Life Systems; the other authors have indicated they have no potential conflicts of interest to disclose.
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
PEDIATRICS Volume 142, number s2, October 2018 S69
in Duchenne muscular dystrophy. Am J Respir Crit Care Med. 1999;160(1):198–202
6. Toussaint M, Steens M, Soudon P. Lung function accurately predicts hypercapnia in patients with Duchenne muscular dystrophy. Chest. 2007;131(2):368–375
7. Birnkrant DJ, Bushby KM, Amin RS, et al. The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol. 2010;45(8):739–748
8. Birnkrant DJ, Bushby K, Bann CM, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347–361
9. Birnkrant DJ, Ararat E, Mhanna MJ. Cardiac phenotype determines survival in Duchenne muscular dystrophy. Pediatr Pulmonol. 2016;51(1):70–76
10. Bach JR, Ishikawa Y, Kim H. Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy. Chest. 1997;112(4):1024–1028
11. Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive ventilatory support prolongs survival. Respir Care. 2011;56(6):744–750
12. Benditt JO, Boitano L. Respiratory support of individuals with Duchenne muscular dystrophy: toward a standard of care. Phys Med Rehabil Clin N Am. 2005;16(4):1125–1139, xii
13. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12(10):926–929
14. Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy–the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17(6):470–475
15. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy: prolongation
of life by noninvasive ventilation and mechanically assisted coughing. Am J Phys Med Rehabil. 2002;81(6):411–415
16. Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul Disord. 2011;21(1):47–51
17. Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax. 1998;53(11):949–952
18. Bushby K, Finkel R, Birnkrant DJ, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177–189
19. Bushby K, Finkel R, Birnkrant DJ, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77–93
20. Humbertclaude V, Hamroun D, Bezzou K, et al. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol. 2012;16(2):149–160
21. Mayer OH, Finkel RS, Rummey C, et al. Characterization of pulmonary function in Duchenne muscular dystrophy. Pediatr Pulmonol. 2015;50(5):487–494
22. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dystrophies. Muscle Nerve. 1981;4(2):155–164
23. Magri F, Govoni A, D’Angelo MG, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258(9):1610–1623
24. Desguerre I, Christov C, Mayer M, et al. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One. 2009;4(2):e4347
25. Gloss D, Moxley RT III, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee
of the American Academy of Neurology. Neurology. 2016;86(5):465–472
26. Sawnani H, Thampratankul L, Szczesniak RD, Fenchel MC, Simakajornboon N. Sleep disordered breathing in young boys with Duchenne muscular dystrophy. J Pediatr. 2015;166(3):640–645.e1
27. Centers for Disease Control and Prevention. Immunization schedules. 2016. Available at: https:// www. cdc. gov/ vaccines/ schedules/ hcp/ index. html. Accessed March 9, 2017
28. Parent Project Muscular Dystrophy. By area vaccination recommendations. Available at: www. parentprojectmd. org/ site/ PageServer? pagename= Care_ area_ vaccinations. Accessed December 10, 2017
29. Bach JR, Bianchi C, Vidigal-Lopes M, Turi S, Felisari G. Lung inflation by glossopharyngeal breathing and “air stacking” in Duchenne muscular dystrophy. Am J Phys Med Rehabil. 2007;86(4):295–300
30. Bach JR, Kang SW. Disorders of ventilation: weakness, stiffness, and mobilization. Chest. 2000;117(2):301–303
31. McKim DA, Katz SL, Barrowman N, Ni A, LeBlanc C. Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy. Arch Phys Med Rehabil. 2012;93(7):1117–1122
32. Stehling F, Bouikidis A, Schara U, Mellies U. Mechanical insufflation/exsufflation improves vital capacity in neuromuscular disorders. Chron Respir Dis. 2015;12(1):31–35
33. Hull J, Aniapravan R, Chan E, et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. Thorax. 2012;67(suppl 1):i1–i40
34. Birnkrant DJ, Panitch HB, Benditt JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest. 2007;132(6):1977–1986
35. Toussaint M, Pernet K, Steens M, Haan J, Sheers N. Cough augmentation in subjects with Duchenne muscular dystrophy: comparison of air stacking
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
SHEEHAN et alS70
via a resuscitator bag versus mechanical ventilation. Respir Care. 2016;61(1):61–67
36. Boitano LJ. Management of airway clearance in neuromuscular disease. Respir Care. 2006;51(8):913–922; discussion 922–924
37. Chatwin M, Ross E, Hart N, Nickol AH, Polkey MI, Simonds AK. Cough augmentation with mechanical insufflation/exsufflation in patients with neuromuscular weakness. Eur Respir J. 2003;21(3):502–508
38. Dohna-Schwake C, Ragette R, Teschler H, Voit T, Mellies U. IPPB-assisted coughing in neuromuscular disorders. Pediatr Pulmonol. 2006;41(6):551–557
39. Fauroux B, Guillemot N, Aubertin G, et al. Physiologic benefits of mechanical insufflation-exsufflation in children with neuromuscular diseases. Chest. 2008;133(1):161–168
40. Homnick DN. Mechanical insufflation-exsufflation for airway mucus clearance [published correction appears in Respir Care. 2011;56(6):888]. Respir Care. 2007;52(10):1296–1305; discussion 1306–1307
41. Miske LJ, Hickey EM, Kolb SM, Weiner DJ, Panitch HB. Use of the mechanical in-exsufflator in pediatric patients with neuromuscular disease and impaired cough. Chest. 2004;125(4):1406–1412
42. Tzeng AC, Bach JR. Prevention of pulmonary morbidity for patients with neuromuscular disease. Chest. 2000;118(5):1390–1396
43. Winck JC, Gonçalves MR, Lourenço C, Viana P, Almeida J, Bach JR. Effects of mechanical insufflation-exsufflation on respiratory parameters for patients with chronic airway secretion encumbrance. Chest. 2004;126(3):774–780
44. Bianchi C, Baiardi P. Cough peak flows: standard values for children and adolescents. Am J Phys Med Rehabil. 2008;87(6):461–467
45. Brito MF, Moreira GA, Pradella-Hallinan M, Tufik S. Air stacking and chest compression increase peak cough flow in patients with Duchenne muscular dystrophy. J Bras Pneumol. 2009;35(10):973–979
46. Daftary AS, Crisanti M, Kalra M, Wong B, Amin R. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics. 2007;119(2). Available at: www. pediatrics. org/ cgi/ content/ full/ 119/ 2/ e320
47. Domènech-Clar R, López-Andreu JA, Compte-Torrero L, et al. Maximal static respiratory pressures in children and adolescents. Pediatr Pulmonol. 2003;35(2):126–132
48. Gauld LM, Boynton A. Relationship between peak cough flow and spirometry in Duchenne muscular dystrophy. Pediatr Pulmonol. 2005;39(5):457–460
49. Ishikawa Y, Bach JR, Komaroff E, Miura T, Jackson-Parekh R. Cough augmentation in Duchenne muscular dystrophy. Am J Phys Med Rehabil. 2008;87(9):726–730
50. Connolly AM, Malkus EC, Mendell JR, et al; MDA DMD Clinical Research Network. Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy. Muscle Nerve. 2015;51(4):522–532
51. Kang SW, Bach JR. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. Am J Phys Med Rehabil. 2000;79(3):222–227
52. Suárez AA, Pessolano FA, Monteiro SG, et al. Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease. Am J Phys Med Rehabil. 2002;81(7):506–511
53. Jain S, Self WH, Wunderink RG; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization. N Engl J Med. 2015;373(24):2382
54. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med. 2001;164(12):2191–2194
55. Finder JD, Birnkrant D, Carl J, et al; American Thoracic Society. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus
statement. Am J Respir Crit Care Med. 2004;170(4):456–465
56. Bersanini C, Khirani S, Ramirez A, et al. Nocturnal hypoxaemia and hypercapnia in children with neuromuscular disorders. Eur Respir J. 2012;39(5):1206–1212
57. Hamada S, Ishikawa Y, Aoyagi T, Ishikawa Y, Minami R, Bach JR. Indicators for ventilator use in Duchenne muscular dystrophy. Respir Med. 2011;105(4):625–629
58. Smith PE, Calverley PM, Edwards RH. Hypoxemia during sleep in Duchenne muscular dystrophy. Am Rev Respir Dis. 1988;137(4):884–888
59. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation–a consensus conference report. Chest. 1999;116(2):521–534
60. Amaddeo A, Moreau J, Frapin A, et al. Long term continuous positive airway pressure (CPAP) and noninvasive ventilation (NIV) in children: initiation criteria in real life. Pediatr Pulmonol. 2016; 51(9):968–974
61. Bach JR, Gonçalves MR, Hamdani I, Winck JC. Extubation of patients with neuromuscular weakness: a new management paradigm. Chest. 2010;137(5):1033–1039
62. Fu ES, Downs JB, Schweiger JW, Miguel RV, Smith RA. Supplemental oxygen impairs detection of hypoventilation by pulse oximetry. Chest. 2004;126(5):1552–1558
63. Rodger S, Woods KL, Bladen CL, et al. Adult care for Duchenne muscular dystrophy in the UK. J Neurol. 2015;262(3):629–641
64. Jeppesen J, Green A, Steffensen BF, Rahbek J. The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscul Disord. 2003;13(10):804–812
65. Toussaint M, Steens M, Wasteels G, Soudon P. Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients. Eur Respir J. 2006;28(3):549–555
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
PEDIATRICS Volume 142, number s2, October 2018 S71
66. McKim DA, Griller N, LeBlanc C, Woolnough A, King J. Twenty-four hour noninvasive ventilation in Duchenne muscular dystrophy: a safe alternative to tracheostomy. Can Respir J. 2013;20(1):e5–e9
67. Bach JR. A comparison of long-term ventilatory support alternatives from the perspective of the patient and care giver. Chest. 1993;104(6):1702–1706
68. CANVent. Phase 4: noninvasive ventilation. 2016. Available at: http:// canventottawa. ca/ Nivam/ Phases/ 4. aspx. Accessed November 13, 2017
69. DMD Pathfinders. Ventilation and Duchenne. 2014. Available at: www. dmdpathfinders. org. uk/ wp- content/ uploads/ 2014/ 11/ dmd- ventilation- faq- booklet- small. pdf. Accessed January 15, 2018
70. Pope JF, Birnkrant DJ. Noninvasive ventilation to facilitate extubation in a pediatric intensive care unit. J Intensive Care Med. 2000;15(2):99–103
71. Finder J, Mayer OH, Sheehan D, et al. Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary. Am J Respir Crit Care Med. 2017;196(4):512–519
72. Won YH, Choi WA, Kim DH, Kang SW. Postural vital capacity difference with aging in Duchenne muscular dystrophy. Muscle Nerve. 2015;52(5):722–727
73. Cho HE, Lee JW, Kang SW, Choi WA, Oh H, Lee KC. Comparison of pulmonary functions at onset of ventilatory insufficiency in patients with amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and myotonic muscular dystrophy. Ann Rehabil Med. 2016;40(1):74–80
74. Just N, Bautin N, Danel-Brunaud V, Debroucker V, Matran R, Perez T.
The Borg dyspnoea score: a relevant clinical marker of inspiratory muscle weakness in amyotrophic lateral sclerosis. Eur Respir J. 2010;35(2):353–360
75. Toussaint M, Soudon P, Kinnear W. Effect of non-invasive ventilation on respiratory muscle loading and endurance in patients with Duchenne muscular dystrophy. Thorax. 2008;63(5):430–434
76. Williamson E, Pederson N, Schaper H. Respiratory muscle training in Duchenne muscular dystrophy: a meta-analysis. Dev Med Child Neurol. 2015;57:57–57
77. Smith PE, Coakley JH, Edwards RH. Respiratory muscle training in Duchenne muscular dystrophy. Muscle Nerve. 1988;11(7):784–785
78. Martin AJ, Stern L, Yeates J, Lepp D, Little J. Respiratory muscle training in Duchenne muscular dystrophy. Dev Med Child Neurol. 1986;28(3):314–318
79. Rodillo E, Noble-Jamieson CM, Aber V, Heckmatt JZ, Muntoni F, Dubowitz V. Respiratory muscle training in Duchenne muscular dystrophy. Arch Dis Child. 1989;64(5):736–738
80. Topin N, Matecki S, Le Bris S, et al. Dose-dependent effect of individualized respiratory muscle training in children with Duchenne muscular dystrophy. Neuromuscul Disord. 2002;12(6):576–583
81. Wanke T, Toifl K, Merkle M, Formanek D, Lahrmann H, Zwick H. Inspiratory muscle training in patients with Duchenne muscular dystrophy. Chest. 1994;105(2):475–482
82. Lechtzin N, Wolfe LF, Frick KD. The impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular
diseases. Ann Am Thorac Soc. 2016;13(6):904–909
83. Toussaint M, De Win H, Steens M, Soudon P. Effect of intrapulmonary percussive ventilation on mucus clearance in Duchenne muscular dystrophy patients: a preliminary report. Respir Care. 2003;48(10):940–947
84. Finder JD. A 2009 perspective on the 2004 American Thoracic Society statement, “respiratory care of the patient with Duchenne muscular dystrophy”. Pediatrics. 2009;123(suppl 4):S239–S241
85. Katz SL, McKim D, Hoey L, et al. Respiratory management strategies for Duchenne muscular dystrophy: practice variation amongst Canadian sub-specialists. Pediatr Pulmonol. 2013;48(1):59–66
86. Andrews JG, Soim A, Pandya S, et al; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Respiratory care received by individuals with Duchenne muscular dystrophy from 2000 to 2011. Respir Care. 2016;61(10):1349–1359
87. Birnkrant DJ, Ashwath ML, Noritz GH, et al. Cardiac and pulmonary function variability in Duchenne/Becker muscular dystrophy: an initial report. J Child Neurol. 2010;25(9):1110–1115
88. Barp A, Bello L, Politano L, et al. Genetic modifiers of Duchenne muscular dystrophy and dilated cardiomyopathy. PLoS One. 2015;10(10):e0141240
89. Swaggart KA, Heydemann A, Palmer AA, McNally EM. Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics. 2011;43(1):24–31
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
DOI: 10.1542/peds.2018-0333H2018;142;S62Pediatrics
D. Sussman and Lisa F. WolfeD. Finder, John Kissel, Richard M. Kravitz, Hemant Sawnani, Richard Shell, Michael Daniel W. Sheehan, David J. Birnkrant, Joshua O. Benditt, Michelle Eagle, JonathanRespiratory Management of the Patient With Duchenne Muscular Dystrophy
ServicesUpdated Information &
http://pediatrics.aappublications.org/content/142/Supplement_2/S62including high resolution figures, can be found at:
References
BIBLhttp://pediatrics.aappublications.org/content/142/Supplement_2/S62#This article cites 85 articles, 18 of which you can access for free at:
Permissions & Licensing
http://www.aappublications.org/site/misc/Permissions.xhtmlin its entirety can be found online at: Information about reproducing this article in parts (figures, tables) or
Reprintshttp://www.aappublications.org/site/misc/reprints.xhtmlInformation about ordering reprints can be found online:
by guest on May 22, 2020www.aappublications.org/newsDownloaded from
DOI: 10.1542/peds.2018-0333H2018;142;S62Pediatrics
D. Sussman and Lisa F. WolfeD. Finder, John Kissel, Richard M. Kravitz, Hemant Sawnani, Richard Shell, Michael Daniel W. Sheehan, David J. Birnkrant, Joshua O. Benditt, Michelle Eagle, JonathanRespiratory Management of the Patient With Duchenne Muscular Dystrophy
http://pediatrics.aappublications.org/content/142/Supplement_2/S62located on the World Wide Web at:
The online version of this article, along with updated information and services, is
http://pediatrics.aappublications.org/content/suppl/2018/09/23/peds.2018-0333H.DCSupplementalData Supplement at:
1073-0397. ISSN:60007. Copyright © 2018 by the American Academy of Pediatrics. All rights reserved. Print
the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois,has been published continuously since 1948. Pediatrics is owned, published, and trademarked by Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it
by guest on May 22, 2020www.aappublications.org/newsDownloaded from